Affiliations 

  • 1 National Poison Control Centre, Military Medical Academy, 17 Crnotravska St, 11000, Belgrade, Republic of Serbia; Medical Faculty of the Military Medical Academy, University of Defence, 1 Pavla Jurišića-Šturma St, 11000, Belgrade, Republic of Serbia; Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanského 62, 50003, Hradec Králové, Czech Republic
  • 2 Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanského 62, 50003, Hradec Králové, Czech Republic
  • 3 Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanského 62, 50003, Hradec Králové, Czech Republic; Malaysia-Japan International Institute of Technology (MJIIT), University Teknologi Malaysia, Jalan Sultan Yahya Petra, 54100, Kuala Lumpur, Malaysia. Electronic address: [email protected]
Chem Biol Interact, 2019 Aug 01;308:312-316.
PMID: 31153983 DOI: 10.1016/j.cbi.2019.05.035

Abstract

K-oximes were developed as modern drug candidates acting as AChE reactivators. In this study, it has been investigated which interspecies and intergender differences changes could be observed in Wistar rats and Swiss mice, both genders, after the treatment with increasing doses of selected acetylcholinesterase reactivators - asoxime, obidoxime, K027, K048, and K075. After the 24 h, a number of died animals was counted and the median lethal dose (LD50) for each oxime was calculated. By using the intramuscular route of administration, asoxime and K027 had the least toxicity in female rats (640.21 mg/kg and 686.08 mg/kg), and in female mice (565.75 mg/kg and 565.74 mg/kg), respectively. Moreover, asoxime and K027 showed 3, 4 or 8 times less acute toxicity in comparison to K048, obidoxime and K075, respectively. Beyond, K075 had the greatest toxicity in male rats (81.53 mg/kg), and in male mice (57.34 mg/kg), respectively. Our results can help to predict likely adverse toxic effects, target organ systems and possible outcome in the event of massive human overexposure, and in establishing risk categories or in dose selection for the initial repeated dose toxicity tests to be conducted for each oxime.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.